SHR-A2102 + adebrelimab

SHR-A2102 + adebrelimab is an investigational combination therapy composed of SHR-A2102, an experimental molecule under clinical evaluation for advanced solid tumors, and adebrelimab, a fully humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1). Adebrelimab blocks the interaction between PD-L1 and PD-1/B7-1, thereby activating T-cells and enhancing the antitumor immune response. The combination is being studied to assess its safety, tolerability, and efficacy primarily in the context of advanced solid tumors, including potential applications in small cell lung cancer and other malignancies[1][2][4].